Down-regulation by growth factors of vascular smooth muscle angiotensin receptor gene expression. 1994

G Nickenig, and T J Murphy
Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia 30322.

The effects of epidermal growth factor, basic fibroblast growth factor, and platelet-derived growth factor-BB on angiotensin type 1 (AT1) receptor gene expression were examined in rat thoracic aorta vascular smooth muscle cells (VSMC) in culture. Incubation of serum-deprived VSMC with 20 ng/ml epidermal growth factor, 20 ng/ml basic fibroblast growth factor, or 50 ng/ml platelet-derived growth factor-BB reduces AT1 receptor mRNA levels, as assessed by Northern hybridization analysis, to approximately 30% of control levels. This effect is maximal 4 hr after addition of each growth factor to the culture medium and is sustained for up to 24 hr of incubation after a single dose. There is a correlative loss of membrane-associated AT1 receptors and angiotensin II-stimulated inositol phosphate production after 24 hr of growth factor treatment. The half-life of AT1 receptor mRNA is reduced significantly by growth factors, compared with that for cells treated with actinomycin D alone to block transcription. This suggests that growth factors activate a mechanism that involves post-transcriptional destabilization of AT1 receptor mRNA. This effect can be blocked by prior treatment of VSMC with actinomycin D or cycloheximide, suggesting that the effect of the growth factors on AT1 receptor gene expression is mediated through induction of an unknown gene or genes that function to destabilize AT1 receptor mRNA and that mRNA translation is essential for the destabilizing effect. Nuclear run-on assays reveal that the growth factors also significantly reduce the rate of de novo AT1 receptor gene transcription. Thus, down-regulation of AT1 receptor gene expression by growth factors also appears to involve mechanisms that decrease the rate of AT1 receptor gene transcription. These data reveal marked down-regulation of AT1 receptor gene expression in VSMC by growth factor receptor activation, through mechanisms that involve both attenuation of transcription and post-transcriptional mRNA destabilization.

UI MeSH Term Description Entries
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010982 Platelet-Derived Growth Factor Mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. Platelet Derived Growth Factor,Factor, Platelet-Derived Growth,Growth Factor, Platelet-Derived
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D000077214 Becaplermin A recombinant human platelet-derived growth factor B-chain dimer used to promote WOUND HEALING by stimulating PHYSIOLOGIC ANGIOGENESIS. PDGF-BB,Platelet-Derived Growth Factor BB,Platelet-Derived Growth Factor BB, Recombinant,Recombinant Platelet-Derived Growth Factor BB,Regranex,rPDGF-BB,rhPDGF-BB,Platelet Derived Growth Factor BB,Platelet Derived Growth Factor BB, Recombinant,Recombinant Platelet Derived Growth Factor BB
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions

Related Publications

G Nickenig, and T J Murphy
February 1996, European journal of pharmacology,
G Nickenig, and T J Murphy
January 1996, Blood pressure. Supplement,
G Nickenig, and T J Murphy
October 1994, The American journal of physiology,
G Nickenig, and T J Murphy
February 2008, Cardiovascular research,
G Nickenig, and T J Murphy
December 2001, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!